How have ATRX shares performed in 2024?

Adhera Therapeutics' stock was trading at $0.03 on January 1st, 2024. Since then, ATRX stock has decreased by 73.3% and is now trading at $0.0080. View the best growth stocks for 2024 here .

Are investors shorting Adhera Therapeutics?

Adhera Therapeutics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 100 shares, a decline of 95.0% from the February 29th total of 2,000 shares. Based on an average daily trading volume, of 220,800 shares, the short-interest ratio is currently 0.0 days. View Adhera Therapeutics' Short Interest .

When did Adhera Therapeutics' stock split?

Shares of Adhera Therapeutics reverse split on Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Adhera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN) , ACADIA Pharmaceuticals (ACAD) , Arbutus Biopharma (ABUS) , Abacus Property Group (ABP) , Advanced BioMedical Technologies (ABMT) , Abiomed (ABMD) , ARCA biopharma (ABIO) , Abeona Therapeutics (ABEO) and Abcam (ABCZY) .

How do I buy shares of Adhera Therapeutics?

Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ATRX

Adhera Therapeutics (ATRX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ATRX Stock Alerts

$0.0079

0.00 (-1.25%)

(As of 02:20 PM ET)

Compare

Today's Range: $0.0072
▼
$0.0090
50-Day Range: $0.0080
▼
$0.0170
52-Week Range: $0.01
▼
$0.60

Volume: 141,500 shs
Average Volume: 122,969 shs
Market Capitalization: $87,532.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials SEC Filings Short Interest

Get Adhera Therapeutics alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Adhera Therapeutics Stock (OTCMKTS:ATRX)

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

ATRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATRX Stock News Headlines

January 30, 2024 | investing.com

Adhera Therapeutics Inc (ATRX)

August 24, 2023 | seekingalpha.com

ATRX Adhera Therapeutics, Inc.

April 16, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

May 22, 2023 | seekingalpha.com

Intensity Therapeutics upsizes proposed IPO to $15M from $8M

February 27, 2023 | finance.yahoo.com

Adhera Therapeutics, Inc. (ATRX)

January 25, 2023 | finance.yahoo.com

Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes

January 18, 2023 | seekingalpha.com

CGTX Cognition Therapeutics, Inc.

December 5, 2022 | seekingalpha.com

Adhera Therapeutics files for Nasdaq uplisting, $35M offering

April 16, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

October 9, 2022 | benzinga.com

Adhera Therapeutics Stock (OTC:ATRXD), Analyst Ratings, Price Targets, Predictions

September 21, 2022 | benzinga.com

Adhera Therapeutics Announces CEO, Senior...

September 19, 2022 | finance.yahoo.com

Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist

September 19, 2022 | seekingalpha.com

Adhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplist

July 19, 2022 | finance.yahoo.com

Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin

May 19, 2022 | seekingalpha.com

Adhera Therapeutics appoints new Chairman of the Board, focuses on uplist to Nasdaq

May 19, 2022 | finance.yahoo.com

Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ

January 20, 2022 | finance.yahoo.com

Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace

November 22, 2021 | finance.yahoo.com

Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders

November 8, 2021 | finance.yahoo.com

Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors

October 20, 2021 | apnews.com

Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary ...

October 20, 2021 | finance.yahoo.com

Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

October 16, 2021 | apnews.com

Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s ...

October 15, 2021 | finance.yahoo.com

Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease

October 4, 2021 | finance.yahoo.com

Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias

September 15, 2021 | insidermonkey.com

5 Penny Stocks with Upcoming Growth Catalysts

September 13, 2021 | apnews.com

Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease ...

September 13, 2021 | finance.yahoo.com

Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs

See More Headlines

Receive ATRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/16/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:ATRX
CUSIP: N/A
CIK: 737207
Web: adherathera.com
Phone: 919-518-3748
Fax: 206-830-9424
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,110,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -5,805.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($7.02) per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 11,080,000
Free Float: 7,955,000
Market Cap: $88,640.00
Optionable: Not Optionable
Beta: -0.15

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Andrew Albert Kucharchuk M.B.A. (Age 43)
Vice Chairman, COO, Acting CFO & Chief Business Officer
Comp: $285k

Key Competitors

View All Competitors

ATRX Stock Analysis - Frequently Asked Questions

How have ATRX shares performed in 2024?: Adhera Therapeutics' stock was trading at $0.03 on January 1st, 2024. Since then, ATRX stock has decreased by 73.3% and is now trading at $0.0080.
View the best growth stocks for 2024 here.
Are investors shorting Adhera Therapeutics?: Adhera Therapeutics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 100 shares, a decline of 95.0% from the February 29th total of 2,000 shares. Based on an average daily trading volume, of 220,800 shares, the short-interest ratio is currently 0.0 days.
View Adhera Therapeutics' Short Interest.
When did Adhera Therapeutics' stock split?: Shares of Adhera Therapeutics reverse split on Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Adhera Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).
How do I buy shares of Adhera Therapeutics?: Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ATRX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adhera Therapeutics (ATRX) Stock Price, News & Analysis

About Adhera Therapeutics Stock (OTCMKTS:ATRX)

ATRX Stock Price History

ATRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ATRX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info